ReviewGels (Basel, Switzerland)2026
Multifunctional Agarose-Based Biomaterials: From Tissue Engineering and Immunomodulation to Advanced Diagnostics and Translational Applications.
Review in Gels (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Agarose, a naturally derived marine polysaccharide extracted from red algae, has evolved from a conventional electrophoretic matrix into a multifunctional biomaterial platform for biomedical engineering. Its thermoreversible gelation, tunable pore structure, optical transparency, generally low immunogenicity under tested conditions, and chemical modifiability enable applications in tissue engineering, drug delivery, molecular diagnostics, immunomodulation, and cell preservation. This review critically examines recent advances in agarose-based biomaterials, with emphasis on structure-property relationships, stimulus-responsive delivery systems, regenerative scaffolds, immune-material interactions, agarose-enabled diagnostic microdevices, and DMSO-free cryopreservation. Representative developments include proof-of-concept microfluidic detection of a cfDNA surrogate and histones in spiked plasma, agarose composite hydrogels for controlled release and osteochondral repair, agarose-containing composite hydrogels investigated for macrophage modulation, and agarose/trehalose systems that provide immediate post-thaw viability comparable to conventional DMSO-based preservation in the reported cell model, although post-thaw proliferation remained lower. Agarose is commercially established in electrophoresis and bioseparation, whereas therapeutic delivery and implantable regenerative systems remain predominantly preclinical. Remaining barriers include limited in vivo degradability, insufficient intrinsic cell adhesiveness and bioactivity, trade-offs among mechanical strength, injectability and printability, and incomplete manufacturing and regulatory standardization. Future work should prioritize well-defined degradation pathways, reproducible composition-property relationships, application-specific benchmarking, and clinically relevant validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.